Sutro biopharma, inc. (STRO)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Dec'17
Assets
Current assets:
Cash and cash equivalents

43,565

4,960

11,954

19,390

26,616

125,298

41,353

22,020

Marketable securities

71,826

112,904

113,209

133,774

143,953

79,194

81,597

-

Accounts receivable (including amounts from related parties of $6,404 and $1,050 as of March 31, 2020 and December 31, 2019, respectively)

9,079

6,298

7,531

6,500

3,338

2,489

2,443

1,624

Prepaid expenses and other current assets

2,989

4,406

2,873

2,559

2,628

2,965

1,979

1,985

Total current assets

127,459

128,568

135,567

162,223

176,535

209,946

127,372

25,629

Property and equipment, net

9,527

9,633

8,522

9,273

9,926

10,934

11,673

13,997

Marketable securities, non-current

14,200

15,600

25,223

15,062

13,747

0

-

-

Other non-current assets

2,683

2,545

2,351

2,239

2,235

2,244

5,966

1,128

Restricted cash

15

15

15

15

15

15

15

15

Total assets

153,875

156,370

171,678

188,812

202,458

223,139

145,026

40,769

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable

5,839

5,584

4,549

4,516

3,395

3,061

4,594

2,902

Accrued compensation

2,944

6,017

4,628

3,565

2,502

6,217

4,085

3,639

Deferred revenue—current

22,873

19,465

20,250

21,380

19,024

21,574

-

10,709

Deferred revenuecurrent

-

-

-

-

-

-

24,229

-

Debt—current

-

1,000

5,843

5,806

5,766

4,724

3,182

14,563

Other current liabilities

352

901

589

832

443

847

815

143

Total current liabilities

32,008

32,967

35,859

36,099

31,130

36,423

36,905

31,956

Deferred revenue, non-current

15,113

16,195

19,849

25,577

31,520

44,599

-

13,159

Deferred revenue, non-current

-

-

-

-

-

-

48,805

-

Deferred rent

373

409

435

456

469

476

473

428

Redeemable convertible preferred stock warrant liability

-

-

-

-

-

-

867

1,708

Debt—non-current

24,155

8,876

5,500

7,000

8,500

10,000

11,500

-

Other noncurrent liabilities

141

134

129

125

121

102

664

14

Total liabilities

71,790

58,581

61,772

69,257

71,740

91,600

99,214

47,265

Commitments and Contingencies

-

-

-

-

-

-

0

-

Redeemable convertible preferred stock, $0.001 par value — zero and 177,082,393 shares authorized as of December 31, 2018 and 2017, respectively; zero and 173,750,421 shares issued and outstanding as of December 31, 2018 and 2017, respectively; no aggregate liquidation preference as of December 31, 2018

-

-

-

-

-

-

187,245

102,505

Stockholders’ equity:
Common stock, $0.001 par value — 300,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 23,227,421 and 23,098,969 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

23

23

23

23

23

23

-

-

Note receivable from stockholder

-

-

-

-

-

-

-

208

Additional paid-in-capital

297,374

293,346

290,616

287,363

284,890

281,891

7,428

6,218

Accumulated other comprehensive income

28

165

223

213

56

-47

-27

-

Accumulated deficit

-215,300

-195,745

-180,956

-168,044

-154,251

-150,328

-148,835

-115,011

Total stockholders’ equity

82,085

97,789

109,906

119,555

130,718

131,539

-141,434

-109,001

Total Liabilities and Stockholders’ Equity

153,875

156,370

171,678

188,812

202,458

223,139

145,026

40,769

Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock, $0.001 par value — zero and 177,082,393 shares authorized as of December 31, 2018 and 2017, respectively; zero and 173,750,421 shares issued and outstanding as of December 31, 2018 and 2017, respectively; no aggregate liquidation preference as of December 31, 2018

-

-

-

-

-

-

-

102,505